NO964468L - Forbindelser og fremgangsmåter for stimulering og forbedring av beskyttende immunresponser og IL-12 produksjon - Google Patents

Forbindelser og fremgangsmåter for stimulering og forbedring av beskyttende immunresponser og IL-12 produksjon

Info

Publication number
NO964468L
NO964468L NO964468A NO964468A NO964468L NO 964468 L NO964468 L NO 964468L NO 964468 A NO964468 A NO 964468A NO 964468 A NO964468 A NO 964468A NO 964468 L NO964468 L NO 964468L
Authority
NO
Norway
Prior art keywords
compounds
stimulating
immune responses
production
methods
Prior art date
Application number
NO964468A
Other languages
English (en)
Norwegian (no)
Other versions
NO964468D0 (no
Inventor
Steven G Reed
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of NO964468D0 publication Critical patent/NO964468D0/no
Publication of NO964468L publication Critical patent/NO964468L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO964468A 1994-04-22 1996-10-21 Forbindelser og fremgangsmåter for stimulering og forbedring av beskyttende immunresponser og IL-12 produksjon NO964468L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23253494A 1994-04-22 1994-04-22
PCT/US1995/005064 WO1995029239A2 (en) 1994-04-22 1995-04-24 Compounds and methods for the stimulation and enhancement of protective immune responses and il-12 production

Publications (2)

Publication Number Publication Date
NO964468D0 NO964468D0 (no) 1996-10-21
NO964468L true NO964468L (no) 1996-12-20

Family

ID=22873521

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964468A NO964468L (no) 1994-04-22 1996-10-21 Forbindelser og fremgangsmåter for stimulering og forbedring av beskyttende immunresponser og IL-12 produksjon

Country Status (15)

Country Link
US (1) US5876966A (de)
EP (1) EP0804581B1 (de)
JP (1) JP3350551B2 (de)
KR (1) KR100358271B1 (de)
CN (1) CN1149887A (de)
AT (1) ATE206163T1 (de)
AU (1) AU695273B2 (de)
BR (1) BR9507505A (de)
CA (1) CA2188543A1 (de)
DE (1) DE69522965T2 (de)
ES (1) ES2161883T3 (de)
NO (1) NO964468L (de)
NZ (1) NZ285238A (de)
PT (1) PT804581E (de)
WO (1) WO1995029239A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879687A (en) * 1994-04-22 1999-03-09 Corixa Corporation Methods for enhancement of protective immune responses
US6013268A (en) * 1994-04-22 2000-01-11 Corixa Corporation Methods for enhancement of protective immune responses
US5876735A (en) * 1994-04-22 1999-03-02 Corixa Corporation Methods for enhancement of protective immune responses
US6500437B1 (en) 1995-09-22 2002-12-31 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6365165B1 (en) 1995-09-22 2002-04-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US6613337B1 (en) 1997-02-12 2003-09-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6607731B1 (en) 1995-09-22 2003-08-19 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US5834592A (en) 1995-09-22 1998-11-10 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US6638517B2 (en) 1995-09-22 2003-10-28 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6375955B1 (en) 1995-09-22 2002-04-23 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6020144A (en) * 1996-09-12 2000-02-01 Symbiontics, Inc. Sustained delivery device comprising a Leishmania protozoa and methods of making and using the same
EP0981624A2 (de) * 1997-02-12 2000-03-01 Corixa Corporation Leishmania antigene zur verwendung in leishmaniasis therapie und diagnose
ATE530651T1 (de) * 1997-02-12 2011-11-15 Corixa Corp Leishmania antigene für verwendung in der therapie und diagnose von leishmaniose
US6517839B1 (en) 1997-07-18 2003-02-11 The Regents Of The University Of California Methods for inducing interleukin-12 and a type1/Th1 T-cell response
EP1115408B1 (de) * 1998-09-23 2006-01-25 Pfeinsmith Limited Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US6892140B1 (en) * 2000-11-27 2005-05-10 Enteron, Inc. Immunogenic cancer peptides and uses thereof
IL155812A0 (en) * 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
US20020193295A1 (en) * 2001-05-04 2002-12-19 Emanuel Calenoff Immunogenic peptides and uses thereof
US20070161087A1 (en) * 2003-05-29 2007-07-12 Wolfgang Glaesner Glp-1 fusion proteins
WO2005062770A2 (en) * 2003-12-19 2005-07-14 Novakoff James L Method for conducting pharmacogenomics-based studies
MY157915A (en) 2004-12-21 2016-08-15 Centocor Inc Anti-il-12 antibodies, epitopes, compositions, methods and uses.
US7833534B2 (en) 2006-04-10 2010-11-16 Infectious Disease Research Institute Compounds and methods for diagnosis and treatment of leishmaniasis
AR073452A1 (es) 2008-07-03 2010-11-10 Infectious Disease Res Inst Proteinas de fusion que comprende dos o mas antigenos de leishmania y su uso en el diagnostico y tratamiento de leishmaniasis
EP2978447B1 (de) 2013-03-28 2019-05-08 Infectious Disease Research Institute Impfstoffe mit leishmania-polypeptiden zur behandlung und diagnose von leishmaniase
CN103837687A (zh) * 2014-03-10 2014-06-04 青岛康立泰药业有限公司 使用具有白细胞介素-12受体的细胞检测重组人白细胞介素-12体外活性的方法及应用
CN109071653A (zh) 2016-03-29 2018-12-21 詹森生物科技公司 用增加的抗-il12和/或-23抗体给药间隔治疗牛皮癣
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
EP3793521A4 (de) 2018-05-18 2022-02-23 Janssen Biotech, Inc. Sichere und wirksame methode zur behandlung von lupus mit anti-il12/il23-antikörper
IL326284A (en) 2018-09-24 2026-04-01 Janssen Biotech Inc A safe and effective method for treating ulcerative colitis with an anti-IL12/IL23 antibody
JP7805788B2 (ja) 2019-05-23 2026-01-26 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
IL298389A (en) 2020-05-21 2023-01-01 Janssen Biotech Inc Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Also Published As

Publication number Publication date
BR9507505A (pt) 1997-09-02
PT804581E (pt) 2002-02-28
EP0804581A1 (de) 1997-11-05
AU2427695A (en) 1995-11-16
NZ285238A (en) 1997-12-19
KR970702367A (ko) 1997-05-13
CA2188543A1 (en) 1995-11-02
ATE206163T1 (de) 2001-10-15
WO1995029239A3 (en) 1995-11-30
DE69522965D1 (de) 2001-10-31
US5876966A (en) 1999-03-02
ES2161883T3 (es) 2001-12-16
WO1995029239A2 (en) 1995-11-02
CN1149887A (zh) 1997-05-14
NO964468D0 (no) 1996-10-21
AU695273B2 (en) 1998-08-13
DE69522965T2 (de) 2002-04-04
JP3350551B2 (ja) 2002-11-25
EP0804581B1 (de) 2001-09-26
JPH09512172A (ja) 1997-12-09
KR100358271B1 (ko) 2003-03-15
MX9604993A (es) 1998-05-31

Similar Documents

Publication Publication Date Title
NO964468D0 (no) Forbindelser og fremgangsmåter for stimulering og forbedring av beskyttende immunresponser og IL-12 produksjon
IT8520110A0 (it) Elettrodo, apparecchiatura e defibrillazione per l'impianto in corpi umani o animali.
ATE314095T1 (de) Virusähnliche partikel zur induktion von autoantikörpern
DK85786A (da) Biologisk aktive fragmenter af human antihaemofilisk faktor og fremgangsmaade til fremstilling deraf
ATE358176T1 (de) Menschliche dnase
DK0708772T3 (da) Imidazo[4,5,-c]pyridin-4-aminer
MX340738B (es) Terapia para deficiencia de a-galactosidasa a.
DE69905368D1 (en) Oxydiertes thymosin beta 4
GB2217330B (en) Lipolytic material associated with cachexia inducing tumours, preparations,production and uses thereof.
ATE464910T1 (de) Humane cd80-mutante und zusammensetzungen und methoden zu deren herstellung und verwendung
NO963029L (no) Anvendelse av IL-10 for å stimulere cytologisk aktivitet av enkjernete celler i perifert blod
DK0841939T3 (da) Terapeutiske midler og autoimmune sygdomme
ZA895840B (en) N-2,3-butadienyl tri-and tetraaminoalkane derivatives
EP0553294A4 (en) Methods and compositions for the treatment of cell proliferation disorders
HU9202075D0 (en) Bcrf1 proteins of gamma-interferon inhibiting effect
ZA884486B (en) Promoters for the expression of foreign dna in methylotrophic bacteria,the obtaining thereof and the use thereof
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
WO2000065028A3 (en) TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR
DE3769497D1 (de) Mittel zur bekaempfung von phytopathogenen mikroben.
GR3018280T3 (en) Primary toxic chemical compounds or allergens, which may be isolated from plant material as well as methods for their preparation and application.
DK1129194T3 (da) Homologt interleukin-1-ZIL1A4
AU5052599A (en) Genetic polymorphisms in the human neurokinin 2 receptor gene and their use in diagnosis and treatment of diseases
MY103584A (en) 8(alpha)-acylaminoergoline, its preparation and pharmaceutical compositions containing it
Cornelissen et al. The discrepancy between handicapped and being human.
UA7955A (uk) Спосіб лікування туберкульозу легенів

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application